<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 27, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774500</url>
  </required_header>
  <id_info>
    <org_study_id>BISTRO</org_study_id>
    <nct_id>NCT01774500</nct_id>
  </id_info>
  <brief_title>Biomarkers In Seizure To Predict Recurrence and Severe Outcomes</brief_title>
  <acronym>BISTRO</acronym>
  <official_title>Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bistro Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bistro Study Group</source>
  <oversight_info>
    <authority>France : comite for Protection of personnes</authority>
    <authority>United Kingdom : Research Ethics comitee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      We study the hypothesis that combination of Proteine S100 beta and Copeptin within normal
      ranges can rule out seizure recurrences and severe outcome, and allow early discharge from
      the emergency department
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective study for a 12 month period in Paris (France) and London (UK).

      Inclusion criteria :

        -  seizure within 24h of attendance to an Emergency department (ED)

        -  or seizure in the ED

      Exclusion Criterie :

        -  pregnancy

        -  prisoneer

      Primary endpoint :

      - recurrence of seizure, hospitalisation more than 24 hours or death within seven days

      Secondary endpoint :

        -  Hospital free days at day 7 and day 28

        -  Death, ICU admission, or neurosurgical intervention at day 7 and day 28

        -  Return visit to the ED or re admission at day 7 and day 28

      data collection:

        -  demographics

        -  past medical history, medication

        -  vital signs (Heart rate, temperature, Pulse oxymetry, blood pressure, GCS) on arrival

        -  Pathology (White cell count, Sodium, Calcium, Glucose, lactate)

        -  Protein S100B and Copeptin

        -  Seizure characteristics (Witnessed, simple, partial, complex, provoked, acute
           symptomatic, idiopathic)

        -  Discharge plan, outcomes

      Follow up at day 7 and day 28, hospital visit or phone call
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>Combined hospital admission, seizure recurrence, or death at day 7</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital free days</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of days out of hospital, death corresponding to 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital free days</measure>
    <time_frame>day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death or ICU admission</measure>
    <time_frame>day 7</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or ICU admission</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of seizure</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Seizures</condition>
  <condition>S-100b Protein</condition>
  <condition>Copeptin</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      2 5ml serum sample for proteine S100Beta and copeptine analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Emergency department patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Seizure within 24 hours of ED attendance

          -  Or Seizure in the ED

        Exclusion Criteria:

          -  Pregnancy

          -  Prisoner

          -  age &lt; 18 years old
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier pitie-salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital, Barts Health NHS Trust</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bistro Study Group</investigator_affiliation>
    <investigator_full_name>Yonathan Freund</investigator_full_name>
    <investigator_title>Chef de Clinique - Research fellow. MD</investigator_title>
  </responsible_party>
  <keyword>biomarkers</keyword>
  <keyword>Emergency Department</keyword>
  <keyword>Seizures</keyword>
  <keyword>epilepsy</keyword>
  <keyword>S100b</keyword>
  <keyword>copeptin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
